Heart Failure: ED Management
MDM Templates
Acute Decompensated Heart Failure — Wet and Warm (Most Common)
Patient presents with dyspnea on exertion + orthopnea in the setting of known heart failure.
Exam reveals peripheral edema + pulmonary crackles.
History, exam, and workup reassure against acute coronary syndrome, serious bacterial infection, acute pulmonary embolus, and other precipitants of decompensation.
Plan:
– Initiated high-dose nitroglycerin (started 50-100 mcg/min IV, titrated to systolic BP and symptoms).
– IV furosemide given (home diuretic dose if on chronic regimen, otherwise 40 mg IV) with reassessment for urine output. BiPAP offered if worsening hypoxia or feeling fatigued.
Disposition: Admit to monitored bed for continued diuresis, optimization of medications (beta-blocker and ACE inhibitor dosing), and assessment of volume status.
Acute Decompensated Heart Failure — Wet and Cold (Cardiogenic Shock)
Patient presents with dyspnea, fatigue, confusion in the setting of severe cardiomyopathy.
Exam reveals hypotension, tachycardia, cool extremities, and pulmonary crackles — consistent with “wet and cold” profile of cardiogenic shock with inadequate perfusion despite congestion.
History and workup do not demonstrate acute myocardial infarction, massive pulmonary embolism, or acute arrhythmia as the primary precipitant, though these remain on the differential.
Plan:
– Initiated cautious vasopressor support — dobutamine 2-5 mcg/kg/min IV infusion titrated to improve blood pressure and end-organ perfusion while monitoring heart rate and arrhythmia.
– Low-dose diuretic (furosemide 20-40 mg IV) used cautiously given hypotension.
– Norepinephrine considered if dopamine/dobutamine ineffective or if systolic pressure remains critically low.
Disposition: Admit to ICU (consideration of mechanical circulatory support if no improvement) with close monitoring of urine output, lactate clearance, and perfusion markers.
HFpEF Exacerbation (Diastolic Heart Failure)
Patient presents with dyspnea, orthopnea, lower extremity edema in the setting of heart failure with preserved ejection fraction.
History and workup do not demonstrate acute coronary syndrome, significant arrhythmia with rapid ventricular response (unless AFib present), or acute infection as primary decompensant.
Plan: Management focused on blood pressure control and slowing heart rate (if needed) to improve diastolic filling time.
– Initiated nitroglycerin IV (50-100 mcg/min) to reduce afterload and relieve congestion.
– If hypertension poorly controlled or AFib with RVR present, additional afterload reduction or rate control addressed.
– Diuretic dosing conservative — these patients are often preload-sensitive and excessive diuresis can precipitate hypotension.
– If new atrial fibrillation, rate control addressed (beta-blocker or diltiazem preferred; digoxin if hemodynamically unstable).
Disposition: Admit if new diagnosis, persistent hypoxia, hypertension difficult to control, or new atrial fibrillation. Many HFpEF exacerbations triggered by hypertensive urgency can be managed as observation if BP improves and oxygen saturations normalize.
Flash Pulmonary Edema (Hypertensive Emergency with Acute Pulmonary Edema)
Patient presents with acute severe dyspnea and pulmonary edema (pink frothy sputum, hypoxia) likely triggered by acute hypertensive surge.
Severely hypertensive but presentation does not suggest acute myocardial infarction, arrhythmia, or infection as primary driver.
Plan: Focused on aggressive vasodilation and reduction of pulmonary edema through afterload reduction, NOT aggressive diuresis.
– Initiated high-dose nitrates — nitroglycerin 400-800 mcg boluses IV or nitroglycerin infusion 100-200 mcg/min titrated aggressively upward; these patients tolerate high doses exceptionally well.
– BiPAP applied immediately at 10/5 cm H2O, titrated to comfort and oxygenation — reduces preload, reduces work of breathing, and buys critical time for medications to work.
Disposition: Admit for continued management and identification of hypertensive trigger.
* Patient typically improves dramatically within 15-30 minutes of aggressive NTG + BiPAP. Diuresis applied conservatively and only after blood pressure is controlled — these patients are not “overloaded” in the traditional sense and excessive diuresis can worsen hypotension and renal perfusion.
Clinical Education
Hemodynamic Profiles and Classification
The Forrester-Stevenson classification characterizes heart failure by two key parameters: pulmonary congestion (“wet” vs “dry”) and systemic perfusion (“warm” vs “cold”). This framework organizes clinical reasoning and guides initial therapy selection.
| Warm (adequate perfusion) | Cold (poor perfusion) | |
| Dry (no congestion) | Warm-dry: Normal hemodynamics (euvolemic, well-compensated) | Cold-dry: Cardiorenal syndrome, reduced renal perfusion without overt congestion (rare in ED) |
| Wet (congestion) | Warm-wet: Volume-overloaded but adequate perfusion (most common ED presentation); crackles, edema, elevated JVP, normal BP, normal lactate | Cold-wet: Cardiogenic shock; congestion + hypotension + end-organ hypoperfusion (highest mortality); the “wet-cold” patient |
Warm-wet is the ED workhorse: These patients are congested (crackles, edema, elevated JVP) but have adequate perfusion (normal blood pressure, normal skin perfusion, alert mental status). They respond exquisitely well to nitroglycerin and diuretics. Wet-cold is the emergency: Hypotension + congestion defines cardiogenic shock. These patients need inotropic support (dobutamine/dopamine) or vasopressors (norepinephrine) before aggressive diuresis.
Nitroglycerin: The Workhorse of Acute Heart Failure
High-dose intravenous nitroglycerin is the single most important drug in acute decompensated heart failure. It works by reducing preload (venous capacitance) and reducing afterload (left ventricular wall stress), both critical in decompensation. It reduces pulmonary congestion rapidly and improves dyspnea within minutes.
Starting regimen: Nitroglycerin IV infusion 50-100 mcg/min, titrated upward aggressively by 50 mcg every 5-10 minutes based on systolic blood pressure and symptom response. Do not be timid with dosing — attendings commonly titrate to 200-400+ mcg/min to achieve symptom relief. Bolus dosing (400-800 mcg IV push over 2-3 minutes) is also effective for rapid symptom improvement, particularly in flash pulmonary edema.[1]
Titration target: Reduce systolic blood pressure by 10-20 mmHg or until symptoms (dyspnea, orthopnea, crackles) improve. In warm-wet patients with normal-to-high blood pressure, aggressive titration is safe and expected. In cardiogenic shock, NTG is deferred or given only after vasopressor support is established, since further blood pressure reduction will worsen perfusion.
Do not be afraid of the dose. Many residents undertreated with NTG because they fear hypotension; in acute heart failure, the problem is almost never “too much NTG,” it is “not enough NTG.” The patient who remains dyspneic on 100 mcg/min needs escalation, not observation.
Important pharmacology: IV nitroglycerin undergoes rapid hepatic metabolism and has a half-life of 3-5 minutes. Effects are seen within 1-2 minutes of infusion start and are completely reversible within minutes of cessation. This rapid kinetics makes it safe for titration and forgiving if side effects develop.
NIPPV (Non-Invasive Positive Pressure Ventilation) and Preload Reduction
BiPAP is first-line alongside NTG in acute pulmonary edema. Positive pressure ventilation reduces preload by increasing intrathoracic pressure (reducing venous return to the right atrium), reduces work of breathing, improves oxygenation, and buys time for medications to work. It is particularly effective in flash pulmonary edema and should be applied early and aggressively.[2]
Starting settings: BiPAP 10/5 cm H2O (inspiratory pressure 10 cm, expiratory pressure 5 cm), with oxygen titrated to target SpO2 >90%. Many ED protocols start immediately on full settings rather than ramping up. Patient comfort and tolerance improve quickly as dyspnea and hypoxia resolve. Continue for a minimum of 30-60 minutes; some patients benefit from several hours of BiPAP.
CPAP vs BiPAP: BiPAP is preferred in acute decompensated heart failure because the lower expiratory pressure is less likely to cause hypotension (a concern in cardiogenic shock). CPAP (continuous positive airway pressure) provides stronger preload reduction but greater hemodynamic risk.
Mechanism of preload reduction: Positive intrathoracic pressure directly compresses the right atrium, reducing venous return. For every 10 cm H2O of positive pressure applied, central venous pressure drops approximately 5 mmHg. This is a direct physical effect, independent of any drug — a critical distinction from diuretic-induced volume loss.
When to escalate to intubation: Most acute heart failure patients improve with NTG + BiPAP + diuretics within 30-60 minutes. Escalate to intubation only if worsening hypoxemia despite BiPAP, altered mental status precluding mask cooperation, or hemodynamic decompensation requiring vasopressor support that cannot be delivered noninvasively.
IV Diuretics
IV furosemide is essential but secondary to NTG + NIPPV. Do not lead with diuretics in acute decompensation; lead with afterload reduction and preload reduction via nitrates and positive pressure, then add diuretics.
Dosing regimen: If the patient is on chronic furosemide, give that home dose IV as the initial bolus (e.g., if they take 40 mg daily, give 40 mg IV; if they take 120 mg daily, give 120 mg IV). If the patient is diuretic-naive or you do not know their home dose, start 40 mg IV furosemide and reassess at 1 hour. Monitor urine output — expect 200+ mL in the first hour with adequate response.
Repeat dosing and intervals: Check urine output at 1 hour. If urine output is brisk (>200 mL), patient is improving clinically, and no worsening renal function, the current dose is adequate. If urine output is poor or patient remains congested, increase the next dose by 50-100% and redose. The goal is not a specific diuretic volume; it is resolution of congestion (crackles cleared, orthopnea resolved, edema improving).
Diuretic resistance: Some patients (particularly those on chronic high-dose diuretics or with advanced cardiorenal syndrome) respond poorly to standard furosemide boluses. Escalation strategies include higher IV doses, more frequent dosing (every 4-6 hours instead of every 8-12 hours), or switching to torsemide (which has better bioavailability than furosemide). Continuous furosemide infusion is also effective for resistant cases but is typically an ICU strategy.
Monitor renal function and electrolytes: Aggressive diuresis can worsen renal function and cause hypokalemia, hyponatremia, and metabolic alkalosis. Check BUN/creatinine and potassium before discharge or ICU transfer.
Flash Pulmonary Edema Pearl: Afterload Mismatch, Not Volume Overload
This is the single most important pearl in heart failure management: Flash pulmonary edema is caused by acute afterload mismatch, not by total-body volume excess. The trigger is a sudden increase in left ventricular afterload (from hypertensive surge) that the heart cannot overcome, causing diastolic pressure to spike acutely and flood the pulmonary vasculature. These patients often do NOT need aggressive diuresis.
Classic presentation: sudden onset of severe dyspnea with frothy pink sputum, triggered by a blood pressure spike to 200+ mmHg systolic. On exam, the patient is in extremis, but examination often reveals a relatively normal or even dry periphery. These patients have NOT been accumulating fluid chronically; they are having acute pulmonary edema from a pressure problem, not a volume problem.
The treatment error: Aggressive diuresis is the classic mistake. These patients improve dramatically with nitroglycerin + BiPAP alone. Giving them large doses of diuretics is counterproductive — it drops preload further, worsens perfusion, and can precipitate hypotension and worsening renal failure without improving their primary problem (afterload mismatch).
The correct approach: Aggressive vasodilation (high-dose NTG) + aggressive preload reduction (BiPAP 10/5) + conservative diuresis. Most flash pulmonary edema patients clear their crackles and oxygenation improves within 15-30 minutes of NTG + BiPAP. Only after blood pressure is controlled and the acute crisis resolves should you add diuretics — and then conservatively.
Recognition tip: Ask yourself: “Did this patient gradually accumulate fluid, or did they acutely develop a pressure crisis?” If flash pulmonary edema followed a sudden spike in blood pressure (or loss of anti-hypertensive medication), this is afterload mismatch. If they have been slowly gaining weight, nocturia, and orthopnea building over days to weeks, they have chronic volume overload (warm-wet ADF). The treatment is different.
Cardiogenic Shock Management
Cardiogenic shock (wet-cold profile) is defined by systolic blood pressure <90 mmHg, signs of hypoperfusion (cool extremities, altered mental status, oliguria, elevated lactate), AND pulmonary or systemic congestion. Mortality is 50% or higher without aggressive intervention.[3]
Inotropic support is mandatory before aggressive diuresis. The goal is to increase cardiac contractility and improve forward flow. Dobutamine 2-5 mcg/kg/min IV is the typical first choice — it increases contractility (beta-1 agonism) and causes mild vasodilation (beta-2 agonism), reducing afterload. Titrate by 2-5 mcg/kg/min every 5-10 minutes based on blood pressure response, aiming for systolic BP >90 mmHg and improvement in perfusion markers.
If dobutamine is inadequate: Escalate to dopamine (which adds alpha-adrenergic (vasoconstriction) at higher doses), or add norepinephrine if systolic pressure remains critically low (<80 mmHg). Milrinone is an alternative inotrope if the patient is already on high-dose beta-blockers (milrinone does not depend on beta-adrenergic receptors). However, milrinone also causes vasodilation and systemic hypotension, making it problematic as monotherapy in shock.
Diuretic dosing in shock: Use minimal diuresis — just enough to keep the patient euvolemic without precipitating further hypotension. In cardiogenic shock, the kidney is being under-perfused; aggressive diuresis worsens renal failure without improving cardiac output. The goal is to improve perfusion through inotropy, not to chase urine output.
Invasive hemodynamic monitoring and mechanical support: Cardiogenic shock that does not rapidly improve with inotropes may require central venous catheter placement for monitoring, or consideration of mechanical circulatory support (intra-aortic balloon pump, Impella, extracorporeal membrane oxygenation). These are ICU/cardiology decisions, but the ED role is to recognize the shock state early and initiate stabilizing therapy while arranging ICU care.
Identifying Precipitants of Heart Failure Decompensation
The patient with decompensated heart failure often has an identifiable trigger. Finding and treating the precipitant is essential for preventing recurrence and for appropriate disposition (e.g., if the patient decompensated from an MI, they need admission; if from dietary salt excess, they may be managed as observation with diuresis and discharge with education).
Common precipitants include: Acute coronary syndrome (troponin, ECG changes, chest pain), new or rapid atrial fibrillation with high ventricular rates (EKG, HR >120), medication noncompliance (ask directly about beta-blockers, ACE inhibitors, diuretics), dietary salt indiscretion (ask about restaurant meals, processed foods, salty snacks in the past 24-48 hours), acute infection (fever, leukocytosis, source on exam), pulmonary embolism (risk factors, hypoxia out of proportion to congestion), thyroid storm or severe hyperthyroidism (tachycardia, tremor, weight loss, fever), hypertensive emergency (very elevated BP as trigger for flash pulmonary edema), and renal failure or electrolyte derangement (hyperkalemia, hypokalemia causing arrhythmia).
Workup to identify precipitants: Troponin (ACS), 12-lead ECG (ACS, arrhythmia rate), CBC (infection), CMP (electrolytes, renal function), BNP (confirms heart failure, not specific for etiology), chest X-ray (pulmonary edema pattern, infection, PE), ECG interpretation for arrhythmia. If clinical suspicion for PE is present (risk factors, hypoxia, unilateral leg swelling), consider D-dimer or CTA PE protocol.
Disposition and Admission Criteria
Admit if any of the following are present: New diagnosis of heart failure (first presentation, unknown EF), persistent hypoxia or oxygen requirement at discharge, hemodynamic instability (systolic BP <90 mmHg, altered mental status, oliguria, elevated lactate, requiring vasopressors/inotropes), worsening renal function from baseline (creatinine rising despite treatment), or patient unable to ambulate safely or manage at home (social factors, frailty, caregiver unavailable).
ICU admission criteria: Cardiogenic shock (wet-cold profile with hypotension), requirement for vasopressor or inotropic support, requirement for mechanical ventilation or high-level NIPPV that cannot be managed on a monitored floor, or profound hypoxia refractory to standard therapy (consider pulmonary edema refractory to NTG + diuretics).
Observation or short-term stay: Some patients with ADF triggered by clear, reversible precipitants (dietary indiscretion, medication noncompliance) who respond rapidly to diuresis and NTG may be observed for 4-6 hours with repeat assessment. If they achieve euvolemia, maintain oxygenation, and remain hemodynamically stable, discharge with close outpatient follow-up (PCP within 3-5 days, cardiology if new diagnosis or EF <35%) is reasonable. Return precautions should include worsening dyspnea, chest pain, syncope, and inability to ambulate.
References
- Aronson D, Burger AJ. Intravenous nitroglycerin in decompensated heart failure: a useful or inert intervention? J Card Fail. 2009;15(5):374-376. PubMed 19477399
- Masip J, Roque M, Sánchez B, Fernández R, Subirana M, Expósito JA. Noninvasive ventilation in acute cardiogenic pulmonary edema: systematic review and meta-analysis. JAMA. 2005;294(24):3124-3130. PubMed 16380593
- Gheorghiade M, Zannad F, Sopko G, et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112(25):3958-3968. PubMed 16365214
- Chioncel O, Parissis J, Maisel A, et al. Acute heart failure syndromes: current state and framework for future research. Eur J Heart Fail. 2022;24(12):2308-2330. PubMed 36194894
- Yancy CW, Jessup M, Bozkurt B, et al. 2023 ACC/AHA/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2023;e1-e108. PubMed
tydotphrase.com 